Business Context and Reporting Period
This Form 8-K is a current report filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata) on March 15, 2012. The registrant is incorporated in Delaware with principal executive offices in Bothell, Washington. The filing serves to disclose a material event under Regulation FD.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
The primary material event reported is the issuance of a press release on March 15, 2012, announcing a Proposed Public Offering. No other material changes to financial position or operations are detailed in this specific document.
Guidance, Outlook, and Risks
- Management Commentary: The company announced a proposed public offering via a press release furnished as Exhibit 99.1.
- Legal Status of Information: In accordance with General Instruction B.2 of Form 8-K, the information in this report and the attached exhibit is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
- Risks/Contingencies: The filing does not explicitly list risks or contingencies beyond the standard regulatory disclaimer regarding the status of the disclosure.
Investor Verification Checklist
- Verify the details of the Proposed Public Offering by reviewing the press release attached as Exhibit 99.1.
- Confirm the current corporate name and status, noting the discrepancy between the metadata ("ACHIEVE LIFE SCIENCES, INC.") and the registrant name in the filing ("ONCOGENEX PHARMACEUTICALS, INC.").
- Check subsequent filings to determine if the proposed offering was completed and to obtain updated financial metrics not present in this 8-K.